Graft-versus-host disease: How to translate new insights into new therapeutic strategies  by Devetten, Marcel P. & Vose, Julie M.
G
I
I
R
s
b
a
i
t
m
o
w
d
s
r
d
w
s
g
B
c
l
T
Biology of Blood and Marrow Transplantation 10:815-825 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1012-0001$30.00/0
doi:10.1016/j.bbmt.2004.10.005
Braft-versus-Host Disease: How to Translate New
nsights into New Therapeutic Strategies
Marcel P. Devetten, Julie M. Vose
University of Nebraska Medical Center, Omaha, Nebraska
Correspondence and reprint requests: Julie M. Vose, MD, University of Nebraska Medical Center, Lied Transplant
Center, Room 8723, 987680 Nebraska Medical Center, Omaha, NE 68198-7680 (e-mail: jmvose@unmc.edu).
Received October 15, 2004; accepted October 15, 2004
ABSTRACT
Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognizemajor or minor histocom-
patibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely
accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to
the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and
differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines.
In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel
treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently
developed interventions aimed to prevent or treat GVHD by interfering with these pathways.
© 2004 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
In 1916, James B. Murphy [1], a researcher at the
ockefeller Institute for Medical Research, ﬁrst ob-
erved that inoculation of the chorioallantoic mem-
rane of chicken embryos with spleen fragments from
dult chickens resulted in the development of dissem-
nated nodules around the site of implantation and on
he splenic surface, as well as marked splenic enlarge-
ent. It was not until the 1950s that the pathophysi-
logic mechanism underlying Murphy’s observation
as elucidated. At that time, Billingham and Brent [2]
escribed how injection of newborn mice with viable
pleen cells from adult donors of a different strain
esulted in the development of what they termed runt
isease. It was the Danish physician Morton Simonsen
ho realized that these were 2 manifestations of the
ame phenomenon and who introduced the name
raft-versus-host disease (GVHD).
The detailed description of runt disease in mice by
illingham [3] will sound remarkably familiar to any
linician dealing with this common complication of al-
ogeneic hematopoietic stem cell transplantation (SCT):
he ﬁrst overt indication of the onset of the disease is a T
B&MThickening and loss of elasticity of the skin, usually ac-
ompanied by erythema of the soles of the feet and the
kin of the ears. Focal areas of epidermal exfoliation
ppear . . . an abrupt cessation of weight gain takes place
. . and in the terminal phase of the disease the animals
requently develop diarrhea. In a small proportion of
nimals, the disease assumes a chronic form from which
hey may sometimes recover.
Billingham deﬁned criteria for the development of
VHD that, with some minor modiﬁcations, are still
alid in 2004:
1) The graft must contain immunologically competent cells.
2) The host must possess important transplantation al-
loantigens that are lacking in the donor graft, so that
the host seems foreign to the graft.
3) The host itself must be incapable of mounting an effec-
tive immunologic reaction against the graft, at least for
sufﬁcient time for the graft to manifest its immunologic
capabilities.
ATHOPHYSIOLOGY OF GVHD
GVHD can occur when transplanted donor-derived
cells recognize major histocompatibility complex
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8MHC) proteins and their associated peptides expressed
y recipient antigen-presenting cells (APCs). Minor his-
ocompatibility antigens also play a role in the develop-
ent of GVHD. A widely accepted paradigm for the
athophysiology of acute GVHD is based on the exis-
ence of 3 sequential phases (Figure 1):
1) Injury to the host environment, resulting in release of
danger signals (afferent phase)
2) Donor T-cell activation, proliferation, and differenti-
ation (afferent phase)
3) Cellular and inﬂammatory attack on target tissues
(efferent phase)
In this article, we brieﬂy review each phase and
iscuss recently developed interventions aimed at pre-
enting or treating GVHD by interfering with path-
ays that are thought to be critical for the develop-
ent of GVHD.
hase 1: Injury to the Host Environment
The ﬁrst phase in the development of GVHD
egins when a conditioning regimen induces tissue
njury, resulting in activation of the immune system.
tudies in mice show that conditioning contributes
irectly to the etiology of GVHD through the release
f proinﬂammatory cytokines, in particular tumor ne-
rosis factor (TNF)– and interleukin (IL)–1 [4]. In
he mouse model, cytokine release results in the acti-
ation of host APCs, and complete abolition of
VHD is possible by inactivation of host APCs [5].
f note, the induction of acute GVHD in this model
oes not require alloantigen expression on host target
igure 1. The pathophysiology of GVHD. A widely accepted para
1) injury to the host environment, resulting in release of danger sig
ellular and inﬂammatory attack on target tissues. APC indicates ant
ost disease; IFN-, interferon ; IL, interleukin; LPS, lipopolysacpithelium, but it is dependent on the release of ﬁ
16NF- and IL-1; neutralization of these cytokines
an prevent GVHD [6].
Recently, Hofmeister et al. [7] described the use of
skin explant model to investigate the effect of total
ody irradiation (TBI) on human skin. They found
hat TBI results in the activation of local skin APCs, as
ell as the induction of premature apoptosis in basal
eratinocytes. The effect of TBI on the gastrointesti-
al tract is even more dramatic; it not only causes
ndothelial apoptosis, resulting in intestinal damage,
ut also allows for immunostimulatory microbial
roducts such as lipopolysaccharide to enter the sys-
emic circulation [8,9]. Interindividual differences in
he extent and severity of GVHD are potentially due
o polymorphisms in important genes involved in the
esponse to injury [10,11].
hase 2: Donor T-Cell Activation, Proliferation,
nd Differentiation
Activation of an alloimmune response begins
hen a donor T-cell receptor binds to an MHC/
eptide complex on a recipient APC. In the presence
f appropriate co-stimulatory signals, transcription of
everal T-cell genes is activated, including nuclear
actor-B and the nuclear factor of activated T cells.
ctivated donor T cells undergo subsequent prolifer-
tion and differentiation [12]. However, some allo-
eactive donor T cells are deleted by a process de-
igned to regulate the severity of the immune response
hrough the induction of tolerance. Two deletional
echanisms of tolerance induction have been identi-
or the pathophysiology of GVHD is based on 3 sequential phases:
) donor T-cell activation, proliferation, and differentiation; and (3)
esenting cell; CTL, cytotoxic T lymphocyte; GVHD, graft-versus-
; NK, natural killer; TNF-, tumor necrosis factor–.digm f
nals; (2
igen-pred: (1) a poorly understood process of central (thy-
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Bic) deletion and (2) a process of peripheral T-cell
poptosis mediated through activation-induced cell
eath (AICD) or passive cell death, which is mediated
y the withdrawal of activation stimuli [13].
CD4/CD25 regulatory T cells (Treg) that can
uppress the expansion of alloreactive T cells have
merged as another important regulator of the
VHD response pathway. In mice, infusion of ex vivo
ctivated and expanded Treg cells can inhibit lethal
VHD, but the role of Treg cells in human GVHD
emains to be elucidated [14,15]. An important role
or human Treg cells in the etiology of GVHD was
orroborated by a recent study from Miura et al. [16].
his study shows that expression of Foxp3 (a transcrip-
ional repressor that seems to be uniquely expressed
y Treg cells) messenger RNA was signiﬁcantly de-
reased in peripheral blood mononuclear cells from
atients with allogeneic or autologous GVHD com-
ared with patients without GVHD. Finally, activated
cells that have escaped deletion will undergo differ-
ntiation characterized by the secretion of cytokines
nd chemokines, most importantly IL-2. The fre-
uency of IL-2–producing cells predicted the occur-
ence of GVHD in a study conducted with a series of
ransplants between HLA-identical siblings [17].
hase 3: Cellular and Inflammatory Effector Phase
Differentiation of activated T cells results in the
roduction of effector cells with the ability to cause
rgan damage by direct cytotoxic activity or through
he production of inﬂammatory cytokines. The cellu-
ar effectors of acute GVHD are primarily cytotoxic T
ymphocytes (CTLs). Much excitement has been cre-
ted by recent reports on the role of natural killer
NK) cells in GVHD. The functions of NK cells are
egulated by a balance of signals transmitted by inhib-
tory receptors that bind class I– and class I–like MHC
olecules and activating receptors, which bind ligands
n tumors and virus-infected cells [18]. Each NK cell
eems to express its own repertoire of activating and
nhibitory receptors, and cytotoxicity is ultimately
able 1. Novel Agents for the Prophylaxis of Acute GVHD
Mechanism of Action Treatment
eduction of proinflammatory
state
Nonmyeloablative conditi
regimen
TNF- inhibitors
IL-2 inhibitors
argeting host APCs Extracorporeal photophor
Alemtuzumab
mmunosuppression Mycophenolate mofetil
Pentostatin
Sirolimus
PC indicates antigen-presenting cells; GVHD, graft-versus-hostegulated by a balance of signals from these receptors. b
B&MTismatch between NK cell receptors and ligands can
esult in NK cell activation and cytotoxicity after
llogeneic SCT. It is interesting to note that such
ctivation seems to mediate a powerful graft-versus-
eukemia (GVL) effect without causing acute GVHD.
n murine models of SCT, infusion of donor NK cells
an reduce GVHD (probably through elimination of
ost APCs). Human studies isolating highly puriﬁed
K cells from normal donors for clinical use are
urrently under way [19].
ROPHYLAXIS OF ACUTE GVHD
ecreasing the Proinflammatory State
Because the conditioning regimen is believed to be
esponsible for injury to host tissue, resulting in the
xpression of “danger signals,” one could speculate that
educed-intensity conditioning regimens should de-
rease the incidence of acute GVHD (Table 1) [20-32].
ouriel et al. [20] recently published study results indi-
ating a signiﬁcantly reduced incidence of both acute and
hronic GVHD in patients who received a nonmyeloa-
lative conditioning regimen before transplantation (as
ompared with patients who received traditional ablative
onditioning). In the group of 137 consecutive patients
ho underwent myeloablative (n  74) or nonmyeloa-
lative (n  63) conditioning before matched related
onor SCT, the incidence of acute GVHD grade II to
V was 34% (95% conﬁdence interval [CI], 24%-48%)
fter myeloablative conditioning, compared with 11%
95%CI, 5%-23%) after nonmyeloablative conditioning
hazard ratio, 3.6). The nonmyeloablative conditioning
roup was characterized by a higher median age, a more
requent use of peripheral blood stem cells (PBSCs), and
higher frequency of lymphoma as the underlying dis-
ase. (No data on late-onset acuteGVHDwere provided
n the publication from Couriel et al. [20].) In a compa-
able study by Mielcarek et al. [21], the incidence of
rade II to IV acute GVHD was reduced after nonmy-
loablative conditioning (64% versus 85%; P  .001),
Results
Reduced incidence of grade II–IV acute GVHD [20,21]
Postponed onset of acute GVHD [22]
Postponed onset of acute GVHD [23,24]
Reduced incidence of grade II–IV acute GVHD [25]
Low incidence of acute and chronic GVHD [26,27]
Incidence of acute GVHD similar to that with treatment
with cyclosporine/methotrexate [28,30,48]
Reduced incidence of grade III–IV acute GVHD (De
Lima, personal communication)
Low incidence of grade II–IV acute GVHD [31,32]
IL-2, interleukin-2; TNF-, tumor necrosis factor–.oning
esisut no difference was noted in the incidence of chronic
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8VHD. In addition, researchers noted a high incidence
f late-onset acute GVHD occurring after day 100. The
ata presented by Mielcarek et al. [21] certainly suggest
hat nonmyeloablative conditioning could result in a
elay in onset rather than a reduction in incidence of
cute GVHD. It would be desirable for future studies to
eport both the incidence of traditional acute GVHD
before day 100) and the incidence of late-onset acute
VHD (after day 100) to deﬁnitively resolve this
ssue.
se of Monoclonal Antibodies against
nflammatory Cytokines
The central role of the inﬂammatory cytokines
L-1 and TNF- early in the afferent phase of GVHD
akes them attractive targets for prophylaxis (Table 1).
n a mouse model, inhibition of IL-1 by in vivo ad-
inistration of an IL-1 receptor antagonist reduced
VHD mortality without affecting engraftment [33].
nfortunately, a double-blind, placebo-controlled
andomized trial of an IL-1 receptor antagonist in 186
atients undergoing SCT did not show any beneﬁt
ssociated with the use of IL-1 blockade [34]. Prophy-
actic administration of monoclonal anti–TNF- as
art of the conditioning regimen in 21 patients un-
ergoing SCT seemed to postpone the onset of acute
VHD when compared with matched historic con-
rols [22]. The recent introduction of several mono-
lonal TNF- inhibitors (etanercept, inﬂiximab, and
dalimumab) in clinical practice should allow for fur-
her testing of this concept, in particular by combining
lockade of IL-1 and TNF- during conditioning.
A few trials have reported on the use of IL-2 inhi-
ition to prevent acute GVHD. In a French study, 101
atients were randomized to receive standard GVHD
rophylaxis with cyclosporine and methotrexate or stan-
ard prophylaxis plus an antibody against the IL-2 re-
eptor [23]. The antibody did not signiﬁcantly affect the
umulative frequency of acute GVHD grade II or
igher, but merely delayed its onset. At a median fol-
ow-up of 58 months, the antibody-treated group had a
igniﬁcantly shorter disease-free survival, mainly because
f a progressive increase in the rate of late relapses.
omparable results were obtained in a small study pub-
ished by Anasetti et al. [24].
More recently, Martin et al. [35] reported their
esults with the use of a CD25-speciﬁc immunotoxin
or the prevention of acute GVHD. CD25 is an acti-
ation antigen that is not present on the surface of
esting T cells but is expressed by alloactivated T cells;
hus, agents targeting CD25 could potentially elimi-
ate alloactivated T cells without compromising im-
une reconstitution. Thirty-six patients received
tandard cyclosporine/methotrexate prophylaxis plus
infusions of immunotoxin after matched unrelated
onor SCT. Acute GVHD grade III/IV developed in
0% of the 35 evaluable patients, compared with 24% d
18f a contemporaneous control group. These unex-
ected results were potentially due to the administra-
ion of cyclosporine, which may have blocked the
nduction of CD25, thereby protecting the alloacti-
ated donor T cells from the effect of the immuno-
oxin, whereas CD25 Treg cells remained suscepti-
le and were inadvertently targeted.
argeting Host APCs
Host APCs are another obvious target for GVHD
revention (Table 1), as has been suggested in murine
VHD studies [5]. Extracorporeal photopheresis
ECP) can inhibit the capacity of circulating APCs to
timulate the proliferation of antigen-stimulated do-
or T cells [36]. During ECP, peripheral blood
ononuclear cells are collected by apheresis, treated
x vivo with the photoactivable drug 8-methoxypso-
alen followed by UV-A irradiation, and then rein-
used to the patient. Miller et al. [25] developed a
ovel conditioning regimen by combining ECP with
ow-dose TBI (600 cGy) and the adenosine deaminase
nhibitor pentostatin. In 55 high-risk patients who
eceived posttransplantation prophylaxis with cyclo-
porine, methotrexate, and mycophenolate mofetil
MMF), the incidence of grade II to IV acute GVHD
as only 9%.
Further studies to elucidate the contribution of
he individual components of this approach to GVHD
rophylaxis are in progress. Attempts to induce T-cell
nergy by blockade of the co-stimulatory signals nec-
ssary for T-cell activation have been developed in in
itro systems and animal models, but these have not
et been translated in large-scale clinical trials [37]. In
small clinical trial (n  12), Guinan et al. [38]
nduced anergy in bone marrow cells from haploiden-
ical donors by coculture with irradiated recipient cells
n the presence of cytotoxic T-lymphocyte–associated
ntigen-4 (CTLA-4), an agent that inhibits B7:CD28-
ediated co-stimulation. Three of 11 evaluable pa-
ients developed acute GVHD, and no deaths were
ttributable to GVHD.
A humanized version of the anti-CD52 antibody
lemtuzumab (Campath-1H; Berlex Laboratories,
ichmond, CA) might have a unique mechanism of
ction, because it seems to prevent GVHD by deple-
ion of host and donor T cells as well as by depletion
f circulating host APCs [39]. Alemtuzumab has been
sed for in vitro T-cell depletion (TCD) of PBSC
rafts, resulting in a very low incidence of acute
8.7%) and chronic (4.4%) GVHD and a 3-year sur-
ival rate of 73% after matched related donor SCT
40]. In vivo administration of alemtuzumab promotes
ngraftment by depletion of host T cells and is not
ssociated with the development of Epstein-Barr vi-
us–associated lymphoproliferative disorder, because
onor B cells are eliminated from the graft [41,42].
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Bhe use of alemtuzumab as part of a nonmyeloablative
onditioning regimen has been associated with very
ow rates of acute and chronic GVHD [26,27]. A
ajor disadvantage associated with the use of alemtu-
umab in vivo seems to be a high incidence of viral
nfections, probably related to the profound immuno-
uppression resulting from depletion of T cells, B
ells, and some APCs [43,44].
ew Immunosuppressive Agents
Several new immunosuppressive agents have been
ested in the setting of allogeneic SCT (Table 1).
MF is a potent, selective, noncompetitive inhibitor
f the type 2 isoform of inosine monophosphate
ehydroxygenase expressed in activated human T and
lymphocytes. By inhibiting inosine monophosphate
ehydroxygenase, MMF depletes the pool of deox-
guanosine triphosphate required for DNA synthesis
45]. MMF was ﬁrst introduced as an important com-
onent of the immunosuppressive regimen required
o sustain engraftment after nonmyeloablative condi-
ioning regimens [46]. An initial study from Born-
auser et al. [47] showed that MMF could be com-
ined with cyclosporine after matched related donor
CT without affecting engraftment. McSweeney et al.
28,48] performed a phase II trial of GVHD prophy-
axis combining tacrolimus with MMF after matched
elated and unrelated donor SCT. Engraftment was
apid (day 10 and day 13 for matched related and
nrelated donor SCT, respectively), and the incidence
f mucositis was low in both groups (likely related to
he omission of methotrexate from the prophylaxis
egimen). The incidence of acute GVHD grade II to
V was 30.3% after matched related donor SCT and
5% after matched unrelated donor SCT. Compara-
le data have been reported by Nash et al. [30]. In this
ose-ﬁnding study of 46 patients undergoing matched
elated donor SCT, a combination of cyclosporin and
MF resulted in an incidence of acute GVHD com-
arable to that observed in a historic control group
hat received prophylactic treatment with cyclospor-
ne and methotrexate.
Pentostatin, a purine nucleoside analog, can in-
uce lymphocyte apoptosis without signiﬁcant myelo-
uppression; therefore, it has potential for use in the
revention of GVHD. De Lima and colleagues (per-
onal communication) at the M. D. Anderson Cancer
enter are currently conducting a randomized con-
rolled trial to determine whether the addition of
entostatin to tacrolimus and minimethotrexate
5 mg/m2 on days 1, 3, 6, and 11 after SCT) after
nrelated and mismatched related SCT can decrease
he incidence of acute GVHD. Patients are being
andomized to prophylaxis with tacrolimus and mini-
ethotrexate (the control arm) or the same prophy-axis with the addition of 1 of several dose schedules of m
B&MTentostatin (0.5, 1, 1.5, or 2 mg/m2 on days 8, 15, 22,
nd 30 with omission of methotrexate on day 11).
eventy-one patients with a median age of 45 years
ave been enrolled to date. At the time of SCT, 58%
f these patients were not in remission, and most
atients received a myeloablative conditioning regi-
en with unrelated donor transplantation. The addi-
ion of pentostatin did not affect the median time to
eutrophil and platelet engraftment. Preliminary eval-
ation suggests a reduction in grade III and IV acute
VHD in the arms receiving pentostatin 1.5 and 2
g/m2.
Sirolimus is the generic name for the natural prod-
ct rapamycin, an agent with antifungal, antitumor,
nd immunosuppressive activities. Structurally similar
o tacrolimus, sirolimus complexes with FK binding
rotein 12 (FKBP12). The search for the intracellular
arget of the sirolimus/FKBP12 complex led to the
iscovery of a pivotal regulator of cell growth and
roliferation: the mammalian target of rapamycin
mTOR). The sirolimus/FKBP12 complex binds di-
ectly to mTOR and inhibits its function, thereby
irectly inhibiting the mTOR-mediated signal trans-
uction pathways and resulting in the arrest of the cell
ycle in the G1 phase [49]. Although there is theoret-
cal competition for FKBP binding sites between
irolimus and calcineurin inhibitors, in vitro studies
how an actual synergy between the agents [50]. The
mmunosuppressive effects of sirolimus result from its
nhibition of T- and B-cell activity. In a study of 41
atients undergoing unrelated donor SCT, combina-
ion immune suppression with tacrolimus, sirolimus,
nd low-dose methotrexate (5 mg/m2 on days 1, 3, 6,
nd 11) resulted in an acute GVHD grade II to IV
ncidence of 26% [31]. In a subsequent study from the
ame group, the combination of sirolimus and tacroli-
us without methotrexate in 30 patients undergoing
atched related SCT was associated with a grade II to
V acute GVHD incidence of 10% [32]. Not a single
atient in this study developed grade III or IV acute
VHD. Further study of these novel agents in com-
ination regimens should result in further improve-
ent of acute GVHD prophylaxis.
se of TCD
On the basis of the central role of donor T cells in
he pathophysiology of GVHD, donor TCD remains
n attractive tool to decrease the incidence of GVHD
nd the morbidity and mortality associated with allo-
eneic SCT (Table 2) [19,51-55]. Animal studies con-
rm that TCD results in low incidences of acute
VHD, allowing transplantation across MHC barri-
rs [56]. In clinical trials, TCD using physical meth-
ds (soybean lectin agglutination with E-rosette de-
letion; counterﬂow centrifugal elutriation) or ex vivo
onoclonal antibodies consistently results in a 25%
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8ncidence of grade II to IV acute GVHD, as long as at
east a 2-log TCD is obtained [51,52]. Unfortunately,
hese studies also demonstrate some of the disadvan-
ages associated with the use of TCD, such as graft
ailure, delay of immune reconstitution, Epstein-Barr
irus–associated lymphoproliferative disorder, and
oss of the GVL effect.
In a prospective multicenter trial, 410 recipients of
n unrelated donor bone marrow graft were random-
zed to GVHD prophylaxis with cyclosporine and
ethotrexate (n  204) or TCD plus cyclosporine
n  201); 5 patients did not undergo transplantation
57]. TCD was achieved by elutriation (n  67) or ex
ivo treatment with anti–T-cell antibodies and com-
lement (n  134). TCD decreased the incidence of
rade III/IV acute GVHD from 27% with cyclospor-
ne/methotrexate to 15% with TCD (P  .01). There
as no difference in the incidence of chronic GVHD
r in 3-year disease-free survival (27% with TCD
ersus 34% with cyclosporine/methotrexate). For the
ubgroup of patients with chronic myelogenous leu-
emia, TCD resulted in a higher incidence of relapse
16% versus 6%; P  .02) and shorter disease-free
urvival (26% versus 40%; P  .17).
Recently, several newer methods of TCD, includ-
ng the use of high-efﬁciency submicroscopic beads
or CD34 selection (CliniMACS device; Miltenyi Bio-
ec GmbH, Bergisch Gladbach, Germany) and in vivo
CD with anti–T-cell antibodies, have resulted in low
ncidences of acute GVHDwhile avoiding some of the
isadvantages associated with TCD. A group from the
niversity of Perugia in Italy have shown that the
D34 cell population contains so-called veto cells,
hich have the ability to neutralize CTL precursors
irected against antigens expressed on CD34 cells
53]. Furthermore, this veto cell population has been
sed to achieve reliable engraftment with a very low
ncidence of acute GVHD (without posttransplanta-
able 2. T-Cell Depletion as Prophylaxis for Acute GVHD
Method of Depletion Results
raditional TCD (E-rosette
depletion, counterflow
centrifugal elutriation)
[51,52]
Low incidence of acute GVHD
(<25%)
Risk of graft failure
Delayed immune recovery
EBV-associated LPD
Loss of GVL effect
D34 selection [53,54] Selects for population enriched
in veto cells
Reliable engraftment
Low incidence of acute GVHD
IR incompatibility [19,55] Low incidence of acute GVHD
Low risk of graft rejection
BV indicates Epstein-Barr virus; GVHD, graft-versus-host dis-
ease; GVL, graft-versus-leukemia; KIR, natural killer cell inhib-
itory receptor; LPD, lymphoproliferative disorder; TCD, T-cell
depletion.ion GVHD prophylaxis) in patients undergoing hap- i
20oidentical SCT, by using megadoses of CD34-se-
ected PBSCs [54].
In a series of elegant experiments, investigators
rom the University of Perugia described the im-
ortance of donor NK cell alloreactivity after T
ell–depleted haploidentical SCT [55]. In 60 con-
ecutive patients with high-risk leukemia, 20 donor-
ecipient pairs with potential for donor-versus-re-
ipient NK cell alloreactivity (GVHD) and 17
onor-recipient pairs with potential for recipient-
ersus-donor alloreactivity (host-versus-graft rejec-
ion) were identiﬁed. Although NK-cell inhibitory
eceptor (KIR) epitope incompatibility predicted
he risk of rejection in 17 donor-recipient pairs,
ejection occurred in only 1 case in this group. In
he group of 20 patients for whom KIR epitope
ncompatibility predicted donor NK cell alloreac-
ivity against recipient cells, no relapses occurred.
ore importantly, the incidence of acute GVHD in
his group was 0%. In a follow-up publication from
he same investigators, the incidence of rejection,
VHD, and relapse in a group of 34 patient-donor
airs with KIR ligand incompatibility was compared
ith these incidences in 58 patient-donor pairs
ithout such incompatibility [19]. For patients with
cute myelogenous leukemia, the outcomes of KIR
igand–incompatible pairs compared favorably to
utcomes in the KIR ligand–compatible pairs (re-
ection, 0% versus 15%; GVHD, 0% versus 14%;
elapse, 0% versus 75%). Thus, intensive TCD has
merged as a potential approach to prevent GVHD
n patients with acute myelogenous leukemia, with
reservation of the GVL effect if donor-recipient
airs can be mismatched for KIR ligand compati-
ility.
Polyclonal antithymocyte globulins (ATGs) have
een used as immunosuppressive agents in clinical
rgan transplantation for many years. Several articles
ave recently appeared on the use of rabbit ATGs to
revent acute and chronic GVHD after unrelated do-
or SCT. Remberger et al. [58] published the results
rom a retrospective comparison of 52 patients in
weden who underwent transplantation after a rabbit
TG–containing conditioning regimen (10 mg/kg)
ompared with matched controls in Seattle who un-
erwent transplantation without rabbit ATG. The
-year cumulative incidence of nonrelapse mortality
as 19% in patients treated with rabbit ATG and 35%
n the control group (hazard ratio, 0.30; 95% CI,
.12-0.75). The reduction in transplant-related mor-
ality was not associated with an increased risk of
elapse (P  .63), except for patients who underwent
ransplantation for chronic myeloid leukemia in ﬁrst
hronic phase. The Alberta Blood and Marrow Trans-
lant Program published their experience with low-
ose rabbit ATG (4.5 mg/kg) as part of the condition-
ng regimen for unrelated donor SCT in 57 patients
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B59]. The incidence of grade II to IV acute GVHD
as 19%, and chronic GVHD was evident in 44%.
onrelapse mortality was 28% at 3 years. Using a
atched pair analysis, the authors showed that toxic-
ty, GVHD incidence, overall survival, and disease-
ree survival were equivalent to those in patients un-
ergoing a matched sibling SCT. Furthermore, data
rom the Gruppo Italiano Trapianti Midollo Osseo
roup in Genova, Italy, show that pretransplantation
abbit ATG administration (3.75-15 mg/kg) decreased
he risk of acute and chronic GVHD and improved
uality of life [60].
There are no randomized trials directly comparing
VHD prophylaxis with and without rabbit ATG.
atched pair analyses and comparisons of genetically
ore homogeneous populations with genetically
ixed populations obviously have to be interpreted
ith caution. Furthermore, some studies suggest that
he dosing of rabbit ATG and day of infusion in
elation to the day of transplantation are additional
mportant factors for the effect on GVHD and im-
une reconstitution [29]. An intriguing property of
abbit ATG is its ability to induce AICD of activated
onor T cells at very low doses [61]. Induction of
ICD would obviously be an attractive tool to poten-
ially decrease acute GVHD without affecting the
VL effect or immune reconstitution. Further studies
xamining the optimal dose and timing of rabbit ATG
dministration, followed by a randomized trial, are
learly needed.
OVEL TREATMENT REGIMENS FOR ESTABLISHED
CUTE GVHD
ew Pharmacologic Agents
Corticosteroids remain the single most effective
gent for the treatment of newly established grade II
o IV acute GVHD. In a retrospective analysis of 443
atients with acute GVHD who received corticoste-
oids, the overall response rate was 55% (complete
esponse rate, 35%; partial response rate, 20%) [62].
owever, the addition of novel agents to these regi-
ens has been the focus of recent studies (Table 3)
63-67]. Lee et al. [68] recently performed a study
able 3. Treatment of Acute GVHD
Study Treatment
berti et al. [64] Etanercept  corticosteroids
ouriel et al. [65] Infliximab
o et al. [66] Denileukin diftitox
olanos-Meade et al. [67] Pentostatin
ee et al. [68] Corticosteroids  daclizumab
R indicates complete response; GVHD, graft-versus-host diseasen the effect of corticosteroids with or without up- r
B&MTront daclizumab, a humanized monoclonal antibody
gainst the IL-2 receptor, in patients with acute
VHD. The study was discontinued early after a
lanned interim analysis showed a signiﬁcantly worse
00-day survival in the group receiving corticosteroids
lus daclizumab (77% versus 94%; P  .02). Prelim-
nary data on the use of the TNF- inhibitor etaner-
ept combined with standard corticosteroids for acute
VHD show an acceptable toxicity and response pro-
le [64].
No standard second-line therapy exists for pa-
ients with steroid-refractory acute GVHD. Although
ommonly used for refractory GVHD, equine ATG
as been associated with a low response rate (approx-
mately 30%) and a high mortality (up to 90%)
69,70]. Incited by the poor results obtained with
TG, several groups have focused on alternative ap-
roaches. Although the trial sizes are small and mature
ata are lacking, promising agents have been identi-
ed. Couriel et al. [65] treated 21 patients with ste-
oid-refractory acute GVHD with inﬂiximab, a mu-
ine-human chimeric monoclonal antibody that binds
he soluble subunit and the membrane-bound precur-
or of TNF-. The overall response rate was 67%,
ith 13 out of 14 responders experiencing complete
esponses. In this study, patients with gastrointestinal
VHD seemed to have the highest likelihood of re-
ponse. Not unexpectedly, infectious complications
ere common, and overall survival remained poor
38%).
Initial data have been published for the use of
enileukin diftitox, a recombinant fusion protein com-
osed of human IL-2 and diphtheria toxin. This drug
as selective activity against activated T cells that is
ased on preferential binding to the high-afﬁnity IL-2
eceptor. In a phase I study of 30 patients with steroid-
efractory acute GVHD, the maximum tolerated dose
f denileukin diftitox was 9 g/kg intravenously on
ays 1, 3, 5, 15, 17, and 19 [66]. At this dose level, 6 of
3 evaluable patients achieved a complete response,
nd 9 of 30 patients were alive at a median follow-up
f 7 months.
In a phase I/II trial from Johns Hopkins, 23 pa-
ients with grade II to IV, biopsy-conﬁrmed, steroid-
Results
ptable toxicity and response profile observed with etanercept
this phase I/II trial
67%
n 6 of 13 patients at a dose of 9 g/kg on days 1, 3, 5, 15, 17, 19
n 14 of 22 patients
y terminated because of worse 100-day survival for daclizumab
oup (77% versus 94%; P .02)
overall response rate.Acce
in
ORR
CR i
CR i
Stud
grefractory acute GVHD were treated with escalating
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8oses of pentostatin (a purine nucleoside analog that
an induce lymphocyte apoptosis) [67]. The dose-
imiting toxicity (infectious complications) was
eached with pentostatin 2 mg/m2/d for 3 days. The
aximum tolerated dose was pentostatin 1.5 mg/m2/d
or 3 days. Of 22 evaluable patients, 14 achieved a
omplete response, and 3 had a partial response.
here were 2 mixed responses, whereas 3 patients
xperienced stable disease and 1 showed progression.
ix of the patients who initially responded experienced
disease ﬂare with acute GVHD and were re-treated;
ll of these patients responded to treatment with the
ame dose of pentostatin. On the basis of these and
ther data, the Bone Marrow Transplant Clinical Tri-
ls Network is initiating a clinical trial for patients
ith newly diagnosed acute GVHD. Patients will be
andomized to receive treatment with standard-dose
orticosteroids combined with 1 of 4 agents: pentosta-
in, denileukin diftitox, etanercept, or MMF. The trial
s designed to rapidly identify new agents with prom-
sing activity against acute GVHD that are suitable for
esting against corticosteroids alone in a subsequent
hase III trial.
Notably, pentostatin has been effective in the
reatment of refractory chronic GVHD, a condition
or which few large randomized trials have been con-
ucted in recent years [71]. Objective responses were
bserved in 56% of patients (n  39) who failed ﬁrst-
r second-line therapy in a phase II study with pen-
ostatin, and many of these patients have been able to
iscontinue steroid medication. Pentostatin seems
articularly active in the treatment of chronic GVHD
n children; an objective response was reported in 15
f 19 pediatric patients with refractory chronic
VHD [72]. These data form the basis for an ongoing
tudy of pentostatin in steroid-refractory pediatric
hronic GVHD by the Pediatric Blood and Marrow
ransplant Consortium. Because of the different
echanisms of action, the combination of ECP with
ther immunomodulatory drugs (eg, pentostatin and
irolimus) could result in the development of syner-
istic combinations that allow for discontinuation or
apering of steroids.
onpharmacologic Approaches
ECP has been tested as a means of treating acute
teroid-refractory GVHD. In a pilot study, Greinix et
l. [73] treated 21 patients with steroid-refractory
cute GVHD with ECP on 2 consecutive days at 1- to
-week intervals until improvement and thereafter ev-
ry 2 to 4 weeks until maximal response. Three
onths after the initiation of ECP, 60% of patients
chieved a complete resolution of GVHD manifesta-
ions, with an overall survival of 57%. These initial
ositive results have since been conﬁrmed in multiple
eports [74]. The mechanism of action that provides r
22he beneﬁcial effect remains a topic of intense inves-
igation. A shift in the subsets of effector T cells from
cytokine proﬁle associated with the T-helper type 1
henotype to a T-helper type 2–dominated cytokine
roﬁle, with an associated shift in dendritic cell im-
unophenotype from type 1 to type 2, has been ob-
erved [36]. Induction of premature lymphocyte se-
escence might also contribute to the effect of ECP
63].
In a fascinating case report, investigators from the
arolinska Institute describe a 9-year-old patient with
efractory severe acute GVHD of the gut and liver
fter an unrelated donor allogeneic SCT [75]. Mesen-
hymal stem cells (MSCs) were obtained from the
one marrow of the patient’s mother, expanded in
itro, and infused at 2  106/kg. MSCs are nonhema-
opoietic stromal cells that can be isolated and ex-
anded from bone marrow. MSCs are minimally im-
unogenic and have been shown to strongly suppress
ixed lymphocyte immune reactions in vitro [76]. In
he reported case study, infusion of MSCs resulted in
apid improvement and, eventually, complete remis-
ion of GVHD. After withdrawal of cyclosporine, the
atient developed recurrent GVHD and was treated
ith another infusion of MSCs (1  106/kg). This
econd infusion also resulted in rapid and complete
esolution of GVHD. This type of complete and long-
asting recovery from severe, treatment-refractory
VHD is extremely uncommon, and one must as-
ume that this resulted from the treatment with hap-
oidentical MSCs. It is interesting to note that the
atient’s lymphocytes had a weak response in mixed-
ymphocyte culture against a pool of lymphocytes
rom 5 random individuals before the MSC infusion;
his reﬂects the profound immune suppression associ-
ted with his previous GVHD treatment. Five weeks
fter the ﬁrst MSC transplantation, the patient’s
ixed lymphocyte response and response to phycohe-
aglutinin increased substantially, indicating some
ecovery of his immune system in the absence of
VHD.
ONCLUSIONS
Insight in the pathophysiology of acute GVHD
as resulted in rational application of new agents for
revention and treatment. Although these agents have
esulted in effective prophylaxis and treatment of mu-
ine GVHD, clinical studies show a more mixed pic-
ure. A model using highly inbred, uniformly treated
ice has limited applicability to the treatment of a
enetically diverse human population with multiple
ifferent diagnoses and pretransplantation treatments.
urther elucidation of the genetic polymorphisms un-
erlying the development of acute GVHD and the
esponse to treatment should eventually result in an
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Bndividualization of acute GVHD prophylaxis. It is
ighly unlikely that future allogeneic SCT will rely on
limited number of conditioning regimens, a single
ource of hematopoietic stem cells, and a standard
ombination of immune suppressive agents. Instead,
ndividual risk proﬁles—including relapse risk, risk for
VHD, and transplant-related mortality—will result
n custom-made combinations of conditioning, stem
ell source, and GVHD prophylaxis for each patient.
n increased understanding of the pathophysiologic
echanisms and additional randomized clinical trials
re needed now if progress is to be expected.
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